Neuroendocrine differentiation in prostatic carcinoma: An update

Prostate

Volumn 36, Issue SUPPL. 8, 1998, Pages 74-79

  Di Sant'Agnese, P Anthony ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Neuroendocrine; Prostate; Prostate cancer

Indexed keywords

ANDROGEN; BOMBESIN; BOMBESIN RECEPTOR; CALCITONIN; CHOLECYSTOKININ; CHROMOGRANIN A; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INVASION; HUMAN; HUMAN CELL; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; TRANSGENIC MOUSE; TUMOR DIFFERENTIATION;

EID: 0008434364     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(1998)8+<74::AID-PROS11>3.0.CO;2-O     Document Type: Article

References (27)

1. di Sant'Agnese P: Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992;70:254-268.
2. di Sant'Agnese P: Neuroendocrine differentiation in prostatic carcinoma. Recent findings and new concepts. Cancer 1995;75:1850-1859.
3. Aprikian A, Han K, Chevalier S, Bazinet M, Viallet J: Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells. J Mol Endocrinol 1996;16:297-306.
4. Aprikian A, Tremblay T, Han K, Landry F, Chevalier S: Bombesin stimulated human prostate cancer cell motility and invasiveness via the tyrosine phosphorylation of focal adhesion kinase PP125FAK and Paxillin. Br J Urol 1997;80:232.
5. Wasilenko W, Cooper J, Palad A, Somers K, Blackmore P, Rhim J, Wright G, Schellhammer P: Calcium signaling in prostate cancer cells evidence for multiple receptors and enhanced sensitivity to bombesin/GRP. Prostate 1997;30:167-173.
6. Han K, Viallet J, Chevalier S, Zheng W, Basinet M, Aprikian A: Characterization of intracellular calcium mobilization by bombesin-related neuropeptides in PC-3 human prostate cancer cells. Prostate 1997;31:53-60.
7. Abdul M, Anezinis P, Logothetis C, Hoosein N: Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res 1994;14:1215-1220.
8. Cramer S, Peehl D, Edgar M, Wong S, Deftos L, Feldman D: Parathyroid hormone-related protein (PTHrP) is an epidermal growth factor-regulated secretory product of human prostatic epithelial cells. Prostate 1996;29:20-29.
9. Cramer S, Chen Z, Peehl D: Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: Inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 1996;156:526-531.
10. Iwamura M, di Sant'Agnese P, Wu G, Benning C, Cockett A, Deftos L: Immunohistochemical localization of parathyroid hormone-related protein in human prostate cancer. Cancer Res 1993;53:1724-1726.
11. Iwamura M, Wu G, Abrahamsson P-A, di Sant'Agnese P, Cockett A, Deftos L: Parathyroid hormone-related protein is expressed by prostatic neuroendocrine cells. Urology 1994;43:667-674.
12. Ritchie C, Thomas K, Andrews L, Tindall D, Fitzpatrick L: Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate 1997;30:183-187.
13. Seethalakshmi I, Mitta S, Dobner P, Menon M, Carraway R: Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 1997;31:183-192.
14. Cohen M, Arber D, Coffield S, Keegan G, McClintock J, Sprights V: Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer 1994;74:1899-1903.
15. Cohen R, Cooper K, Haffejee Z, Robinson E, Beckers P: Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer. Pathology 1995;27:229-232.
16. Faris G, Stein A, Sova Y, Lurie M, Lurie A: Chromogranin is a marker for neuroendocrine differentiation in prostate carcinoma of various grades and stages. J Urol Pathol 1995;29-35.
17. Dema A, Raica M, Tudose N: Prognostic significance of neuroendocrine differentiation in carcinoma of the prostate. Morphol Embryol 1996;42:83-88.
18. Bubendorf L, Sauter G, Moch H, Schmid H, Gasser T, Jordan P, Mihatsch M: Ki67 labelling index: An independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996;178:437-441.
19. Bohrer M, Schmoll J: Immunohistochemical and morphometric studies on neuroendocrine differentiation of prostate carcinomas. Verh Dtsch Ges Pathol 1993;77:107-110.
20. Allen F, Van Velden D, Heyns C: Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer? Br J Urol 1995;75:751-754.
21. McWilliam L, Manson C, George N: Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. Br J Urol 1997;80:287-290.
22. Speights V, Cohen M, Riggs M, Coffield K, Keegan G, Arber D: Neuroendocrine stains and proliferative indices of prostatic adenocarcinomas in transurethral resection samples. Br J Urol 1997;80:281-286.
23. Noordzii M, van der Kwast T, van Steenbrugge G, Hop W, Schroder F: The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 1995;62:252-258.
24. Weinstein M, Partin A, Veltri R, Epstein J: Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996;27:683-687.
25. Krijnen J, Bogdanowicz J, Seldenrijk C, Mulder P, can der Kwast T: The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997;158:171-174.
26. Hoosein N, Abdul M, McCabe R, Gero A, Deftos L, Banks M, Hodges S, Finn L, Logothetis C: Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urol Oncol 1995;1:246-251.
27. Cussenot O, Villette J, Valeri A, Cariou G, Desgrandchamos F, Cortese A, Meria P, Teillac P, Piet J, Le Duc A: Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996;155:1340-1343.